2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum

This continuing education activity reviews best practices in the growing field of radiotheragnostics (aka theranostics or theragnostics) for benign and malignant diseases, beginning with the fundamentals and extending to include advanced clinical applications. A review of historically established therapies that have been optimally modernized as well as the recently introduced state-of-the-art modalities are included. The expert faculty discuss the optimization of the radiotheragnostic practices for best utilization of various radiopharmaceuticals in contemporary health care delivery systems, both academic and private practice settings.

This meeting is designed for nuclear medicine physicians, nuclear radiologists, oncologists, health physicists, and radiopharmacists.

Educational Symposia

Physicians: Educational Symposia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Educational Symposia designates this enduring material for a maximum of 10.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All activity participants are required to take a written or online test in order to be awarded credit. All course participants will also have the opportunity to critically evaluate the program as it relates to practice relevance and educational objectives.

AMA PRA Category 1 Credit(s)^TM for these programs may be claimed until February 14, 2024.

This program is planned and organized by Educational Symposia, a leader in accredited continuing education since 1975.

This CME activity was planned and produced in accordance with the ACCME Essential Areas and Elements.

At the completion of this CME activity, subscribers should be able to:

• The difference between the radiotheragnostic approach and various other concepts guiding the therapeutic delivery of radiation to the target tissues with the objective of improving health outcomes.
• The best therapeutic practice approaches to hyperthyroidism and other benign thyroid diseases, based on evidence and/or sound medical judgment.
• The best therapeutic practice approaches to differentiated thyroid carcinoma, based on evidence and/or sound medical judgment.
• The optimal applications of Y-90 Ibritumomab Tiuxetan for therapy of lymphoma.
• The optimal applications of I-131 Iobenguane to diagnostic imaging and therapy of Pheochromocytoma and Paraganglioma.
• The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.
• The optimal applications of Ga-68 Dotatate Imaging and Lu-177 Dotatate therapy of neuroendocrine tumors.
• The optimal approach to diagnostic imaging of recurrent and metastatic prostate cancer.
• The best approach to therapy of skeletal metastatic disease using various Bone-Seeking radiopharmaceuticals.
• The practical examples for evaluation of not listed cancers for radiotheragnostics-based trials.
• Best approaches to building radiotheragnostic practice in academic institutions.
• Best approaches to building radiotheragnostic practice in private practice settings.

No special educational preparation is required for this CME activity